These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24614711)

  • 21. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
    Urvanegia AC; Tavoloni Braga JC; Shitara D; Fregnani JH; Neves JI; Pinto CA; Marghoob AA; Duprat JP; Rezze GG
    PLoS One; 2017; 12(6):e0179745. PubMed ID: 28662062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
    Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
    Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.
    Capper D; Berghoff AS; Magerle M; Ilhan A; Wöhrer A; Hackl M; Pichler J; Pusch S; Meyer J; Habel A; Petzelbauer P; Birner P; von Deimling A; Preusser M
    Acta Neuropathol; 2012 Feb; 123(2):223-33. PubMed ID: 22012135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
    Nguyen LP; Emley A; Wajapeyee N; Green MR; Mahalingam M
    Br J Dermatol; 2010 Mar; 162(3):677-80. PubMed ID: 19919630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
    Greaves WO; Verma S; Patel KP; Davies MA; Barkoh BA; Galbincea JM; Yao H; Lazar AJ; Aldape KD; Medeiros LJ; Luthra R
    J Mol Diagn; 2013 Mar; 15(2):220-6. PubMed ID: 23273605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
    Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
    J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
    Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
    Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.